pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›LEQVIO
drug · oligonucleotide
save

LEQVIO

updated 6mo ago
by $NVS NOVARTIS AG🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 2
  • druginclisiran32 co-mentions · 8 sources
  • tagApproval32 co-mentions · 8 sources

Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.

targets

PCSK9 mRNA

all catalysts(0)

nothing on the calendar yet

Trials studying LEQVIO

  • phase4LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Loweringrecruitingn=100
  • phase3Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Eventsactive not recruitingn=610
  • phase4Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Interventionrecruitingn=6,000
  • phase2Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemiarecruitingn=216
  • phase3A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.active not recruitingn=14,012
  • phase3Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Diseaseactive not recruitingn=17,004
  • phase4Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemiacompletedn=1,770
  • phase2A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemiacompletedn=156

News(10)

  • Novartis projects slowed growth, pins hopes on billions in pipeline potential
    With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.
    biospace · 4h ago
  • Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment
    Despite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.
    fiercebiotech · 16h ago
  • Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
    Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
    biospace · 23d ago
  • Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
    Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
    fiercebiotech · 2mo ago
  • Scribe’s early-stage IPO standout defies biotech’s derisking trend
    Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
    biospace · 3mo ago
  • Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
    The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
    biopharma_dive · 3mo ago
  • Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
    In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
    fiercebiotech · 3mo ago
  • Novartis climbs on upbeat drug sales as key readouts loom
    A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
    biopharma_dive · 4mo ago
  • Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
    Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
    fiercebiotech · 4mo ago
  • Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
    Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
    biospace · 4mo ago
view all news mentions →
brand
LEQVIO
trade names
Leqvio
generic
INCLISIRAN SODIUM
MOA
12.1 Mechanism of Action Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.
indication
1 INDICATIONS AND USAGE LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. ( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?